MicroRNA-29 (miR-29)

MicroRNA-29 is a small, non-coding RNA molecule and member of the microRNA family involved in the post-transcriptional regulation of gene expression. It comprises three main homologs in humans—miR-29a, miR-29b, and miR-29c—encoded by two gene clusters. MicroRNA-29 exerts its functions by binding the 3′ untranslated regions of target mRNAs, leading to translational repression or mRNA degradation. It regulates diverse biological processes including cell differentiation (particularly osteoblast, neuronal, and macrophage lineages), apoptosis, immune modulation, extracellular matrix synthesis (notably as an antifibrotic agent), and DNA methylation via direct targeting of DNMT3A and DNMT3B. Dysregulation of miR-29 expression has been linked to multiple pathological conditions including cancer, fibrotic diseases of numerous organs, neurological conditions such as Alzheimer’s disease and neurodevelopmental disorders, cardiovascular disease, metabolic syndromes such as NAFLD, and age-associated tissue degeneration. MicroRNA-29 is considered a promising therapeutic target, with experimental strategies involving either inhibition or restoration of its function, though no drugs are currently approved. Key challenges include managing its pleiotropic effects and mitigating the risk of adverse events due to its broad regulatory network[1][3][4][5][6][7][8][9][10][11][12].

Other names

miR-29miRNA-29miR-29amiR-29bmiR-29cMIR29AMIR29B1MIR29B2MIR29Chsa-miR-29hsa-miR-29ahsa-miR-29bhsa-miR-29c

Antisense oligonucleotide inhibition of miR-29 (e.g., anti-miR-29) blocks its function, affecting target mRNA expression. miR-29 mimics restore miR-29 activity in disease contexts with loss of expression, leading to repression of fibrotic or oncogenic genes.